C-reactive protein and risk of breast cancer: A systematic review and meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Guo, Lanwei ^a   Liu, Shuzheng ^a   Zhang, Shaokai ^a   Chen, Qiong ^a   Zhang, Meng ^a   Quan, Peiliang ^a   Lu, Jianbang ^a   Sun, Xibin ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST TUMOR; CAUCASIAN; FACTUAL DATABASE; FEMALE; HUMAN; META ANALYSIS; METABOLISM; ODDS RATIO; PATHOLOGY; RISK FACTOR;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; C-REACTIVE PROTEIN; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; ODDS RATIO; RISK FACTORS;

EID: 84930202034     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10508     Document Type: Article

References (36)

1. Ferlay, J. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, Fr. Int. Agency Res. Cancer. 2013. Available from: http://globocan.iarc.fr, accessed on 11/20/2014.
2. Maccio, A., Madeddu, C. & Mantovani, G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes. Rev. 10, 660-670 (2009).
3. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? The lancet 357, 539-545 (2001).
4. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444 (2008).
5. Mahmoud, F. A. & Rivera, N. I. The role of C-reactive protein as a prognostic indicator in advanced cancer. Current Oncology Reports 4, 250-255 (2002).
6. Pearson, T. A. et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 107, 499-511 (2003).
7. Libby, P., Ridker, P. M. & Hansson, G. K. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol 54, 2129-2138 (2009).
8. Heikkilä, K. et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20, 15-26 (2009).
9. Poole, E. M. et al. A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor a receptor 2 levels and risk of ovarian cancer. Am. J. Epidemiol, kwt098 (2013).
10. Allin, K. H., Bojesen, S. E. & Nordestgaard, B. G. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 27, 2217-2224 (2009).
11. Alokail, M. S. et al. Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk? BMC Cancer 13, 54 (2013).
12. Dossus, L. et al. C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. Cancer Causes Control 25, 533-539 (2014).
13. Gaudet, M. M. et al. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int. J. Mol. Epidemiol. Genet 4, 156 (2013).
14. Hong, T. et al. Preoperative serum C-reactive protein levels and early breast cancer by BMI and menopausal status. Cancer Invest. 31, 279-285 (2013).
15. Il'yasova, D. et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 14, 2413-2418 (2005).
16. Ollberding, N. J. et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev. Res. (Phila) 6, 188-195 (2013).
17. Prizment, A. E. et al. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. Cancer Causes Control 24, 2077-2087 (2013).
18. Siemes, C. et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J. Clin. Oncol. 24, 5216-5222 (2006).
19. Touvier, M. et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am. J. Epidemiol. 177, 3-13 (2013).
20. Van Hemelrijck, M. et al. Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol. Biomarkers Prev. 20, 428-437 (2011).
21. Zeleniuch-Jacquotte, A. et al. Re: C-reactive protein and risk of breast cancer. J. Natl. Cancer Inst. 100, 443-444 (2008).
22. Zhang, S. M. et al. C-reactive protein and risk of breast cancer. J. Natl. Cancer Inst. 99, 890-894 (2007).
23. Wang, G. et al. A prospective follow-up study of the relationship between C-Reactive Protein and human cancer risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomarkers Prev. doi: 10.1158/1055-9965.EPI-14-1112 (2014).
24. Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579-591 (2004).
25. Wiseman, M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc. Nutr. Soc. 67, 253-256 (2008).
26. Das, U. Is obesity an inflammatory condition? Nutrition 17, 953-966 (2001).
27. Gualillo, O., Lago, F., Casanueva, F. F. & Dieguez, C. One ancestor, several peptides: Post-translational modifications of preproghrelin generate several peptides with antithetical effects. Mol. Cell Endocrinol. 256, 1-8 (2006).
28. Wellen, K. E. & Hotamisligil, G. S. Obesity-induced inflammatory changes in adipose tissue. The J. Clin. Invest. 112, 1785-1788 (2003).
29. Ockene, I. S. et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clinical Chemistry 47, 444-450 (2001).
30. Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemio. 32, 1-22 (2003).
31. Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Davey Smith, G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat. Med. 27, 1133-1163 (2008).
32. Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719-748 (1959).
33. DerSimonian, R. & Kacker, R. Random-effects model for meta-analysis of clinical trials: an update. Contemp. Clin. Trials 28, 105-114 (2007).
34. Orsini, N., Bellocco, R. & Greenland, S. Generalized least squares for trend estimation of summarized dose-response data. Stata. Journal 6, 40-57 (2006).
35. Greenland, S. & Longnecker, M. P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am. J. Epidemiol. 135, 1301-1309 (1992).
36. Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539-1558 (2002).